TL;DR: 🟢 Landmark positive — first mechanical circulatory support device to show a mortality benefit in STEMI-cardiogenic shock (45.8% vs 58.5%, P=0.04), though with more bleeding/complications.
1. Publication
- Title: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock
- Acronym: DanGer Shock
- Year & Journal: New England Journal of Medicine, published April 7, 2024 (390(15):1382-1393)
- Citation: Møller JE, Engstrøm T, Jensen LO, et al; DanGer Shock Investigators. N Engl J Med. 2024;390(15):1382-1393. doi:10.1056/NEJMoa2312572
2. Context & Rationale
Background: Cardiogenic shock is a frequent, morbid complication of STEMI. Microaxial flow pumps (MAFP, e.g., Impella CP) unload the LV and augment cardiac output, but prior small RCTs showed no benefit, with registry data suggesting possible bleeding-related harm.
Research Question/Hypothesis: In STEMI patients with cardiogenic shock, does routine microaxial flow pump use plus standard care reduce 180-day all-cause mortality compared with standard care alone?
3. Design & Methods
- Study Type: International, multicenter RCT (originally single-country DanShock, expanded to Germany 2019, UK 2021)
- Population: STEMI with cardiogenic shock, planned emergency revascularization; randomized in cath lab before/after revascularization or up to 12h after
- Intervention: Microaxial flow pump (Impella CP) plus standard care (n=179)
- Comparator: Standard care alone (n=176)
- Randomization: Web-based, stratified by STEMI location and revascularization timing; 360 randomized, 355 analyzed
- Statistical Power & Follow-Up: Primary: death from any cause at 180 days. Safety: composite of severe bleeding, limb ischemia, hemolysis, device failure, worsening aortic regurgitation.
4. Key Results
355 patients analyzed (179 mAFP, 176 standard care). Median age 67y, 79.2% male.
Outcome | Microaxial Flow Pump | Standard Care | Effect Size | 95% CI | p-value | Notes |
Death from any cause at 180d (primary) | 45.8% (82/179) | 58.5% (103/176) | HR 0.74 | 0.55–0.99 | 0.04 | Significant benefit |
Composite safety endpoint | Higher | Lower | — | — | — | More bleeding, limb ischemia, hemolysis, device failure with mAFP |
5. Internal Validity Assessment
International, multicenter RCT (expanded from single-country after slow enrollment) with hard mortality endpoint. Overall: Strong — statistically significant mortality benefit despite prior negative smaller trials; the concurrent safety signal (more adverse events) is an important, real tradeoff rather than a limitation undermining the primary finding.
6. External Validity Assessment
Danish/German/UK STEMI-cardiogenic-shock population — an independent NEJM correspondence noted this was "a highly selected group of patients with minimal risk of possible hypoxic brain injury," a nuance for generalizing to broader, less-selected cardiogenic shock populations.
7. Strengths & Limitations
Strengths: First RCT to show a mortality benefit from mechanical circulatory support in STEMI-cardiogenic shock, contrasting with prior IABP, VA-ECMO, and earlier microaxial-pump trials; rigorous, prospectively expanded multicenter design.
Limitations: Increased adverse events (bleeding, limb ischemia, hemolysis) with the device; industry funding (Abiomed) alongside Danish Heart Foundation; population selection (minimal hypoxic brain injury risk) may limit generalizability to broader shock populations, per independent commentary.
8. Interpretation & Practice Impact
Supports routine microaxial flow pump use in carefully selected STEMI-cardiogenic-shock patients — the first mechanical circulatory support device to show a mortality benefit in this population, though the increased adverse event rate requires careful patient selection and vigilant complication management.
9. Controversies & Subsequent Evidence
An accompanying NEJM editorial ("Mechanical Circulatory Support in Cardiogenic Shock — Persistence and Progress") frames this as a genuine advance after decades of neutral/negative device trials in this space. Subsequent correspondence and secondary analyses (e.g., renal outcomes, Circulation 2025) continue mining this landmark dataset; a comparative study (Waksman et al.) directly compared IABP vs microaxial flow pump outcomes.
10. Summary & Executive Takeaway
Summary: DanGer Shock randomized 355 STEMI-cardiogenic-shock patients to microaxial flow pump plus standard care or standard care alone. 180-day mortality was significantly lower with the device (45.8% vs 58.5%, HR 0.74, P=0.04), but composite adverse events (bleeding, limb ischemia, hemolysis, device failure) were more common.
Overall Takeaway: DanGer Shock is the first trial to demonstrate a genuine mortality benefit from mechanical circulatory support in STEMI-cardiogenic shock — a landmark, practice-changing result, tempered by a real increase in device-related complications requiring careful patient selection.
11. Bibliography
- Thiele H, et al. IABP-SHOCK II. N Engl J Med. 2012;367:1287-1296.
- Udesen NJ, Møller JE, et al. Rationale and design of DanGer Shock. Am Heart J. 2019;214:60-68.